Return to Listing

13 result(s) for Prostate

PI Name Protocol # Title
Julie Graff IRB00005254 A Phase II Study of CTLA Blockade by Ipilimumab plus Androgen Suppression Therapy in Patients with an Incomplete Response to AST Alone for Metastatic Prostate Cancer
Tomasz Beer IRB00005688 A Phase II study of MAOA inhibitor plus docetaxel in patients receiving and progressing on docetaxel therapy
Joshi Alumkal IRB00008791 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
Tomasz Beer IRB00009204 Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms of Resistance
Joshi Alumkal IRB00009259 Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
Julie Graff IRB00009352 A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
Julie Graff IRB00009363 PVAMC / OHSU J: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Joshi Alumkal IRB00010241 Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Xin Li IRB00010345 Contrast Enhanced MRI of the Prostate
Tomasz Beer IRB00010479 A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Julie Graff IRB00011025 PVAMC / OHSU J: Addition of Pembrolizumab Upon Progression on Enzalutamide in men with mCRPC
Arthur Hung IRB00011268 Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide (MDV3100) in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
Kerri Winters IRB00011765 Health & Mobility in Prostate Cancer Survivors
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080